Výsledky vyhledávání - "James, Witek"

Akademický článek

Lumicitabine, an orally administered nucleoside analog, in infants hospitalized with respiratory syncytial virus (RSV) infection: Safety, efficacy, and pharmacokinetic results.

Autor: Abbie Oey, Matthew McClure, Julian A Symons, Sushmita Chanda, John Fry, Patrick F Smith, Kathia Luciani, Michael Fayon, Kulkanya Chokephaibulkit, Rattapon Uppala, Jolanta Bernatoniene, Kenji Furuno, Thorsten Stanley, Dymphy Huntjens, James Witek, and RSV2004 Study Groups

Publikováno v: PLoS ONE, Vol 18, Iss 7, p e0288271 (2023)

Respiratory syncytial virus (RSV) infection is the leading cause of infant hospitalizations and mortality. Lumicitabine, an oral nucleoside analog was studied for the treatment of RSV. The phase 1b and phase 2b studies reported here assessed the safe

Externí odkaz: https://doaj.org/article/13cf6106ec36481f850eae5b8cb9155b

Zobrazit plný text záznamu

Measuring respiratory syncytial virus infection severity in hospitalized children using the Pediatric Respiratory Syncytial Virus Electronic Severity and Outcome Rating System (PRESORS)

Autor: Yannick Vandendijck, Jane Scott, Dirk Heerwegh, Wim Van Der Elst, James Witek, Rekha Sinha, Hein Fennema

Publikováno v: Influenza Other Respir Viruses

BACKGROUND: The Pediatric Respiratory Syncytial Virus Electronic Severity and Outcome Rating System (PRESORS) was developed to assess the severity of respiratory syncytial virus (RSV) infection in children. Because young children cannot report how th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a089f062a9d2c4ad63b04e9d15e5c51
https://doi.org/10.1111/irv.13028

Zobrazit plný text záznamu

Plný text ve formátu HTML

Akademický článek

Efficacy of telaprevir-based therapy in stable liver transplant patients with chronic genotype 1 hepatitis C

Autor: Xavier Forns, Didier Samuel, David Mutimer, Stefano Fagiuoli, Miquel Navasa, Kosh Agarwal, Marina Berenguer, Massimo Colombo, Kerstin Herzer, Frederik Nevens, Bjorn Daems, Katrien Janssen, Sivi Ouwerkerk-Mahadevan, Holly Kimko, Erkki Lathouwers, James Witek, Rodica Van Solingen-Ristea

Publikováno v: Annals of Hepatology, Vol 15, Iss 4, Pp 512-523 (2016)

Background and rationale. The REPLACE study (NCT01571583) investigated telaprevir-based triple therapy in patients who have recurrent genotype 1 hepatitis C virus (HCV) infection following liver transplantation and are on a stable immunosuppressant r

Externí odkaz: https://doaj.org/article/b851a19ac46e4b3cb62b33c6ad84da6e

Zobrazit plný text záznamu

Risk Factors and Medical Resource Utilization of Respiratory Syncytial Virus, Human Metapneumovirus and Influenza Related Hospitalizations in Adults – A Global Study During the 2017-2019 Epidemic Seasons (Hospitalized Acute Respiratory Tract Infection [HARTI] Study)

Autor: Yannick Vandenijck, Xiaohui Ren, Edward E. Walsh, James Witek, Stacey L. House, Sofia Keim, Ann R. Falsey, Pascale Peeters, Diye Kang, Gabriela Ispas

Publikováno v: Open Forum Infectious Diseases.

Background Respiratory syncytial virus (RSV), human metapneumovirus (hMPV) and influenza are respiratory pathogens leading to hospitalization in adults. Understanding disease burden is limited to data from single-center or one-season studies in elder

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3ddcd406ed140bd732782ffd38f57140
https://doi.org/10.1093/ofid/ofab491

Zobrazit plný text záznamu

The Hospital Recovery Scale: A clinically useful endpoint in patients hospitalized with influenza

Autor: Wilbert, van Duijnhoven, Ilse, Van Dromme, Steven, Haesendonckx, James, Witek, Lorant, Leopold

Publikováno v: Contemporary Clinical Trials. 123:106952

Currently, no single best primary endpoint exists for measuring the efficacy of treatments in seriously ill patients with respiratory infections, such as influenza, who require hospitalization. The Hospital Recovery Scale is an ordinal endpoint used

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::95f98deaa25a7e57b5c86b451671a7bc
https://doi.org/10.1016/j.cct.2022.106952

Zobrazit plný text záznamu

Comparative assessment of reported symptoms of influenza, respiratory syncytial virus, and human metapneumovirus infection during hospitalization and post-discharge assessed by Respiratory Intensity and Impact Questionnaire

Autor: Eric K. H. Chan, Diye Kang, Edward E. Walsh, Gabriela Ispas, Yannick Vandendijck, Richard H. Osborne, Jane Scott, James Witek, Xiaohui Ren, Ann R. Falsey

Publikováno v: Influenza and Other Respiratory Viruses

Background The hospitalized acute respiratory tract infection (HARTI) study used the Respiratory Intensity and Impact Questionnaire (RiiQ™) Symptom Scale, derived from FluiiQ™, to assess and compare the burden of respiratory infection symptoms fo

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2d487a47a2d0f8a053a7504fbb960d02
https://pubmed.ncbi.nlm.nih.gov/34472708

Zobrazit plný text záznamu

Simeprevir plus peginterferon/ribavirin for HCV genotype 1-infected treatment-naïve patients in China and South Korea

Autor: Jun Cheng, Sivi Ouwerkerk-Mahadevan, Qing Xie, Thierry Verbinnen, Eva Hoeben, Jia Shang, Lai Wei, James Witek, Oliver Lenz, Ju Hyun Kim, Jeong Heo, Mengchun Li, Xinyue Chen, Jane Scott, Monika Peeters, Dongliang Yang, R. Kalmeijer, Tao Han, Rekha Sinha

Publikováno v: Journal of Gastroenterology and Hepatology. 31:912-920

Background and Aim Approximately one-third of patients with hepatitis C virus (HCV) genotype (GT) 1 infection live in East Asia. This study evaluated the efficacy, pharmacokinetics, safety, and tolerability of simeprevir plus peginterferon alpha-2a a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6a9e5df29e5abfdefb1827743a3ab0e5
https://doi.org/10.1111/jgh.13288

Zobrazit plný text záznamu

Simeprevir plus sofosbuvir (12 and 8 weeks) in hepatitis C virus genotype 1‐infected patients without cirrhosis: OPTIMIST‐1, a phase 3, randomized study

Autor: David E. Bernstein, Bart Fevery, Paul Y. Kwo, Eugene R. Schiff, Rekha Sinha, M. Davis, Ronald Nahass, Jane Scott, Norman Gitlin, James Witek, R. Kalmeijer, Monika Peeters, Sergio Rojter, Peter Ruane, Guy De La Rosa, K.P. Etzkorn, Oliver Lenz, Ziad Younes

Publikováno v: Hepatology (Baltimore, Md.)

Effective antiviral therapy is essential for achieving sustained virological response (SVR) in hepatitis C virus (HCV)-infected patients. The phase 2 COSMOS study reported high SVR rates in treatment-naive and prior null-responder HCV genotype (GT) 1

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::deadbc48ce67ec8a149e5c3c72075988
http://europepmc.org/articles/PMC5412860

Zobrazit plný text záznamu

Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: A phase 3 study (OPTIMIST‐2)

Publikováno v: Hepatology (Baltimore, Md.)

UNLABELLED Hepatitis C virus (HCV)-infected patients with cirrhosis are historically a difficult-to-treat population and are at risk of hepatic decompensation. In the phase 2 COSMOS study that evaluated simeprevir (HCV NS3/4A protease inhibitor) + so

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1cc98c5801eb45ef1c93d898a7703ba
https://doi.org/10.1002/hep.28422

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání